Tag: biosimilars

Biologic Patent Protection: When Biosimilars Can Enter the U.S. Market

Biologic drugs in the U.S. enjoy 12 years of exclusivity before biosimilars can enter, delaying affordable alternatives. Learn how patent laws, complex development, and litigation block competition-and who pays the price.

Read More

Biologic Drugs: Why They Can't Be Copied Like Regular Medicines

Biologic drugs are made from living cells, not chemicals, making them too complex to copy exactly. That’s why biosimilars exist - they’re highly similar, but not identical. Learn why manufacturing them is like farming proteins, and why generics can’t compete.

Read More

What Are Biosimilars? A Simple Guide for Patients

Biosimilars are highly similar versions of complex biologic drugs that work just as well but cost less. Learn how they differ from generics, why they're safe, and what you need to know as a patient.

Read More